Forma Therapeutics, Inc.
Clinical trials sponsored by Forma Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing therapies for rare diseases and cancer, acquired by Novo Nordisk.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could shield kids with sickle cell from stroke Results expected Aug 2027 (estimated) May already have reported ↗
-
New pill aims to boost red blood cells in MDS patients
Disease control Stopped earlyThis phase 2 trial tested a daily pill called etavopivat in 17 adults with very low, low, or intermediate risk MDS who had anemia. The goal was to see if the drug could improve red blood cell counts and reduce the need for transfusions. The study was terminated early, so the full…
Phase 2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Fatty liver drug trial halted early: what we know
Disease control Stopped earlyThis early-stage study tested an experimental drug called FT-4101 in 14 overweight or obese adults with NASH, a serious fatty liver disease. The main goals were to check safety and see if the drug could reduce liver fat. The study was stopped early, so results are limited.
Phase 1/2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC